[Osteoclastogenesis inhibitory factor/osteoprotegerin(OCIF/OPG)].
Tomoyasu
Akihiro
A
Research Planning & Coordination Department, Chugai Pharmaceutical Co., Ltd.
Higashio
Kanji
K
D000818:Animals; D002454:Cell Differentiation / Q000187:drug effects*; D003864:Depression, Chemical; D015195:Drug Design; D006023:Glycoproteins / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use; D006801:Humans; D010010:Osteoclasts / Q000166:cytology*; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology / Q000627:therapeutic use; D018124:Receptors, Tumor Necrosis Factor
D006023:Glycoproteins; D053244:Osteoprotegerin; D018160:Receptors, Cytoplasmic and Nuclear; D018124:Receptors, Tumor Necrosis Factor; C506030:TNFRSF11B protein, human